| For: | Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol 2016; 22(6): 2118-2125 [PMID: 26877616 DOI: 10.3748/wjg.v22.i6.2118] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i6/2118.htm |
| Number | Citing Articles |
| 1 |
L. M. Tchoumba Tchoumi, M. L. Nchouwet, S. L. Poualeu Kamani, W. Yousseu Nana, R. C. Douho Djimeli, A. Kamanyi, S. L. Wansi Ngnokam. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats. Advances in Traditional Medicine 2021; 21(3) doi: 10.1007/s13596-020-00470-6
|
| 2 |
Lehar Khanna, Thorvardur R. Halfdanarson, Mohamad B. Sonbol, Rachel Eiring, Teresa Prond, Michael Camilleri. Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. Digestive Diseases and Sciences 2022; 67(6) doi: 10.1007/s10620-021-07189-7
|
| 3 |
V. N. Joish, F. Frech, P. Lapuerta. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. Journal of Medical Economics 2018; 21(2) doi: 10.1080/13696998.2017.1387120
|
| 4 |
Arvind Dasari, Vijay N. Joish, Raul Perez-Olle, Sam Dharba, Kavitha Balaji, Daniel M. Halperin. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020; 20(5) doi: 10.1080/14737167.2019.1660646
|
| 5 |
Boniface Pone Kamdem, Brice Rostan Pinlap, Bijou-Lafortune Noumboue Kouamou, Aubin Youbi Kamche, Boris Arnaud Kuate, Joseph Tsemeugne, Orleans Ngomo, Pierre Mkounga, Fabrice Fekam Boyom. Repurposing Synthetic Acetaminophen Derivatives Containing a Benzothiazole Scaffold as an Alternative Therapy for Infectious Diarrhea Caused by Drug-Resistant Shigella Species. Future Pharmacology 2024; 4(2) doi: 10.3390/futurepharmacol4020023
|
| 6 |
M.E. Pavel, E. Baudin, K.E. Öberg, J.D. Hainsworth, M. Voi, N. Rouyrre, M. Peeters, D.J. Gross, J.C. Yao. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Annals of Oncology 2017; 28(7) doi: 10.1093/annonc/mdx193
|
| 7 |
Julie Hallet, C. H. L. Law, M. Cheung, N. Mittmann, N. Liu, H. D. Fischer, S. Singh. Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis. Annals of Surgical Oncology 2017; 24(11) doi: 10.1245/s10434-017-5986-0
|
| 8 |
Tanya Burton, Pablo Lapuerta. Economic Analysis of Inadequate Symptom Control in Carcinoid Cyndrome in the United States. Future Oncology 2018; 14(23) doi: 10.2217/fon-2018-0129
|
| 9 |
Matthew H Kulke, Hagen F Kennecke, Kris Murali, Vijay N Joish. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study. Cancer Management and Research 2021; doi: 10.2147/CMAR.S330429
|
| 10 |
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, Amy J. Purvis, Thomas M. O'Dorisio, Thorvardur R. Halfdanarson. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019; 48(8) doi: 10.1097/MPA.0000000000001384
|
| 11 |
Arvind Dasari, Vijay N Joish, Raul Perez-Olle, Samyukta Dharba, Kavitha Balaji, Daniel M Halperin. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World Journal of Gastroenterology 2019; 25(47): 6857-6865 doi: 10.3748/wjg.v25.i47.6857
|
| 12 |
Yue Cheng, Lowell Anthony, Chris Delcher, Daniela C Moga, Aman Chauhan, Bin Huang, Val Adams. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors. The Oncologist 2023; 28(6) doi: 10.1093/oncolo/oyad057
|
| 13 |
Marine Perrier, Charbel Mouawad, Delphine Gueguen, Benoit Thomé, Maryse Lapeyre-Mestre, Thomas Walter. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database. Clinics and Research in Hepatology and Gastroenterology 2023; 47(7) doi: 10.1016/j.clinre.2023.102177
|
| 14 |
Jonathan Strosberg, Vijay N. Joish, Susan Giacalone, Raul Perez-Olle, Ann Fish-Steagall, Kanika Kapoor, Sam Dharba, Pablo Lapuerta, Al B. Benson. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. The Oncologist 2019; 24(11) doi: 10.1634/theoncologist.2018-0921
|
| 15 |
Al B. Benson, Jonathan Strosberg, Vijay N. Joish, Samyukta Dharba, Dipa Sapre, Pablo Lapuerta. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. Pancreas 2020; 49(3) doi: 10.1097/MPA.0000000000001496
|
| 16 |
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P. Neary, Mei S. Duh, Al B. Benson. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017; 20(9) doi: 10.1080/13696998.2017.1337019
|
| 17 |
Lowell B. Anthony, Thomas M. O'Dorisio. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. The Oncologist 2021; 26(7) doi: 10.1002/onco.13847
|
| 18 |
I-Wen Pan, Daniel M. Halperin, Bumyang Kim, James C. Yao, Ya-Chen Tina Shih. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. PharmacoEconomics 2021; 39(11) doi: 10.1007/s40273-021-01071-0
|
| 19 |
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Carcinoid-syndrome: recent advances, current status and controversies. Current Opinion in Endocrinology, Diabetes & Obesity 2018; 25(1) doi: 10.1097/MED.0000000000000376
|
| 20 |
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca, Marta Trapero-Bertran. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism 2019; 10 doi: 10.1177/2042018819828217
|
| 21 |
Louisa G. Gordon, Thomas M. Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Segelov, David K. Wyld. The Economic Impact on Australian Patients with Neuroendocrine Tumours. The Patient - Patient-Centered Outcomes Research 2020; 13(3) doi: 10.1007/s40271-020-00412-z
|
| 22 |
Michel Archange Fokam Tagne, Paul Aimé Noubissi, Gaëtan Olivier Fankem, René Kamgang. Effects ofOxalis barrelieriL. (Oxalidaceae) aqueous extract on diarrhea induced byShigella dysenteriaetype 1 in rats. Health Science Reports 2018; 1(2) doi: 10.1002/hsr2.20
|
| 23 |
G.R. de Almeida, R.P. Riechelmann, A.B. Brito, R.G. Taboada, A.L.M. da Silva, R.F. Weschenfelder, A.P.B.S. Etges. Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors. ESMO Gastrointestinal Oncology 2026; 12 doi: 10.1016/j.esmogo.2026.100337
|
| 24 |
Joseph S Dillon, Chandrikha Chandrasekharan. Telotristat Ethyl: A Novel Agent for the Therapy of Carcinoid Syndrome Diarrhea. Future Oncology 2018; 14(12) doi: 10.2217/fon-2017-0340
|
| 25 |
Vijay N. Joish, Feride Frech, Pablo Lapuerta. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clinical Therapeutics 2017; 39(12) doi: 10.1016/j.clinthera.2017.10.019
|
| 26 |
A. Custodio, P. Jimenez-Fonseca, A. Carmona-Bayonas, M. J. Gomez, M. I. Del Olmo-García, I. Lorenzo, J. Á. Díaz, N. Canal, G. De la Cruz, C. Villabona. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clinical and Translational Oncology 2021; 23(10) doi: 10.1007/s12094-021-02608-7
|
| 27 |
Kira Oleinikov, Shani Avniel-Polak, David J. Gross, Simona Grozinsky-Glasberg. Carcinoid Syndrome: Updates and Review of Current Therapy. Current Treatment Options in Oncology 2019; 20(9) doi: 10.1007/s11864-019-0671-0
|
| 28 |
Kelly Fust, Michael Maschio, Michele Kohli, Simron Singh, D. Mark Pritchard, Florence Marteau, Peter Myrenfors, Marion Feuilly. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020; 38(6) doi: 10.1007/s40273-020-00896-5
|
| 29 |
Dieter Hörsch, Lowell Anthony, David J. Gross, Juan W. Valle, Staffan Welin, Marta Benavent, Martyn Caplin, Marianne Pavel, Emily Bergsland, Kjell Öberg, Kenneth B. Kassler-Taub, Polina Binder, Phillip Banks, Pablo Lapuerta, Matthew H. Kulke. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology 2022; 112(3) doi: 10.1159/000516958
|